Diatech files INDs for two peptides
Peptide-based imaging agent developer Diatech has filed two investigationalnew drug (IND) applications with the Food and Drug Administrationfor technetium-99m-labeled radiopharmaceuticals. Diatech, of Londonderry,NH, reported the news this month. The
Peptide-based imaging agent developer Diatech has filed two investigationalnew drug (IND) applications with the Food and Drug Administrationfor technetium-99m-labeled radiopharmaceuticals. Diatech, of Londonderry,NH, reported the news this month.
The first agent, Tc-99m P748, is for the rapid detection ofpulmonary embolism. The peptide binds to a glycoprotein receptorlocated at activated platelets involved in blood clots. The secondagent, Tc-99m P829, is a somatostatin peptide for localizing canceroustumors. Diatech claims that a study presented at last year's RadiologicalSociety of North America meeting indicated that an agent closelyrelated to P829 may have better target to non-target ratios comparedto OctreoScan, a peptide-based imaging agent released by MallinckrodtMedical last year (SCAN 6/15/94).
The IND filings bring to five the number of Diatech productsin clinical trials, according to Diatech president Richard Dean.Diatech is also developing peptide-based radiopharmaceuticalsfor the detection of deep-vein thrombosis and atherosclerosisand for the treatment of bone metastases.
Seven Takeaways from Meta-Analysis of PSMA Radiotracers for Prostate Cancer Imaging
December 1st 2023In a newly published meta-analysis of 24 studies, researchers noted that the PSMA PET radiotracer 18F PSMA-1007 may provide more benefit than 68Ga Ga-PSMA-11 for primary staging of patients with prostate cancer and detection of local lesion recurrence, but also has drawbacks with higher liver uptake and multiple reports of false positive bone lesions.
GE HealthCare Launches AI Mammography Platform with Key Applications from iCAD
November 30th 2023Offering an all-in-one platform of artificial intelligence (AI) applications, MyBreastAI Suite reportedly facilitates early breast cancer detection and enhances efficiency with breast imaging workflows.
